SIRs for tAML by calendar year after initial chemotherapy treatment of selected first primary malignancies in adulthood, 9 SEER registries, 1975-2008.P-values were derived from Poisson regression models adjusted for age at first primary malignancy diagnosis, receipt of initial radiotherapy, sex (for lung and bronchus, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma), stage (for lung and bronchus, female breast, and ovary), and latency (overall: 1.0-4.9, 5.0-9.9, 10+ years; for lung and bronchus, 1-4.9, 5+ years; 1-4.9 years: 1.0-2.9, 3.0-4.9 years). CI, confidence interval; P_hom, p for homogeneity; tAML, therapy-related acute myeloid leukemia; SIR, standardized incidence ratio; SEER, Surveillance, Epidemiology and End Results.